AEGiS-Bangkok Post: Panel will decide fate of V-1 Immunitor; Report could lead to registration as drug Bangkok PostImportant note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
Click here to return to Bangkok Post main menu
DonateNow



Panel will decide fate of V-1 Immunitor; Report could lead to registration as drug

Bangkok Post - June 2, 2001
Kosol Satithamajit


An official panel could decide the fate of V-1 Immunitor after the government intervened in a dispute between a medical clinic and Aids activists.

A joint panel between the Public Health Ministry and the Salang Bunnag Foundation, whose clinic hands out the pills, will look into the drug's effectiveness in treating Aids.

Public Health Minister Sudarat Keyuraphan said the ministry would approve the distribution of V-1 Immunitor if the panel found it useful.

The decision came after a three-and-a-half-hour meeting to settle a conflict between the foundation and Aids activist groups.

Deputy Prime Minister Pithak Intaravithayanan, who chaired the meeting, said the panel would comprise Department of Communicable Disease Control head Somsong Rakpao, foundation chairman Salang Bunnag, and well-known academics.

Mr Pithak said the panel would look into the effectiveness of V-1 Immunitor before deciding whether to allow the substance to be registered, which would make its distribution legitimate.

V-1 Immunitor is registered by the Food and Drug Administration as a food supplement. Pol Gen Salang's Bang Pakong clinic in Chachoengsao has been handing it out free to HIV/Aids patients.

The ministry stepped in after learning that patients were told to stop using established drugs in favour of V-1 Immunitor.

The ministry said stopping those drugs would do more harm than good and that patients should not be misled into thinking V-I Immunitor could cure HIV/Aids until there was scientific proof.

Bangkok Senator Jon Ungphakorn, a top anti-Aids activist, said the foundation had exaggerated V-1 Immunitor's quality.

As it was not approved as a legal drug it was not safe for consumption, he said.

However, Pol Gen Salang said criticisms were motivated by self-interest. Activist groups backed established anti-Aids drugs, whose import price would be affected if V-1 Immunitor were to be registered as a legal drug.

Mrs Sudarat said there was no point in obstructing V-1 Immunitor if it could help Thailand save money from importing Aids drugs.

The foundation plans to hand out V-1 Immunitor free at the Thai-Japanese Stadium today, although the ministry has imposed curbs on its distribution campaign.

The meeting decided to allow the foundation to carry on with its campaign, on condition it was done under a doctor's supervision, and that the foundation stop calling V-1 Immunitor a drug.

It was also told to stop telling patients that it could cure Aids.
010602
BP010602


Copyright © 2001 - The Bangkok Post. Reproduction of this article (other than one copy for personal reference) must be cleared through the Bangkok Post.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .